{"name":"TYK Medicines, Inc","slug":"tyk-medicines-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Abiraptor","genericName":"Abiraptor","slug":"abiraptor","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TY-9591","genericName":"TY-9591","slug":"ty-9591","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Abiraptor","genericName":"Abiraptor","slug":"abiraptor","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TY-9591","genericName":"TY-9591","slug":"ty-9591","phase":"phase_3","mechanism":"TY-9591 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPUjc5LVJ4dnJkdWdPVElCNjY3SnBHWUV1WHI1akpCRE44WnFTN2k0ckFjeG52Y2lhQzN6bjByMXpOU3hHUjBfVkxFSUpjN2xZSXhiaExGR2JoYnJIUWFTSUZZelcxZEFqd0JmNW9uVWtvN1dWV19vcFk3Y3dKQ2JqODR1d0hwRHVPWHFiMTAxX1JDUGc1VWFnLUZWNA?oc=5","date":"2026-03-24","type":"pipeline","source":"openPR.com","summary":"EGFR Non Small Cell Lung Cancer Pipeline 2026: Key Companies, - openPR.com","headline":"EGFR Non Small Cell Lung Cancer Pipeline 2026: Key Companies,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPUU9GX21ndGt0WW1pWjVVOUZld0gtM09LcC1BLURCMjgxckI0VGV4MXduQTJ4eDNGTkN1SU8wcnBkTlFfeW5rMFlJU1FabUVTVFE1eC12czZZMzhKQzdvVU1ORmZSTjhaV3NzaHU3Rjl3WS1taXQ4dHJCV1NMb2dBVmphRldfcUpWOFRxZG9pOElaS1RmR1VtTw?oc=5","date":"2026-03-20","type":"trial","source":"openPR.com","summary":"Breast Cancer Clinical Trial Gains Momentum: 250+ Companies - openPR.com","headline":"Breast Cancer Clinical Trial Gains Momentum: 250+ Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOUlVMMXYwNlFRS2U3cVAxdGx1UHktMU45dEJmODFSZTV2NUFQNmRKZkdZa3YxWUdZOTdBLTE3SmJmblVHNUpRT194cTc0eGlvcDlfR1UtajJXZ2gwaHlqbS1sY3lzWUIwRVc3cjdjRlRkazYwRWJZX2xRMGJILUgxbjhOV3pTRW1MOXloOXZEcGw0YUJCRFRvMFltNHpCZEdoTWJfNldFaXZFbGo0bE4xX2RndHdacnMyZHRtOXVDNEhXMFRGa0xaajhRQ1d3cFhNRTlwcXpESE4xS1BtaFFHbXppaHUzVS1SNzc2YXJVZkZENEliQXNfRjBR?oc=5","date":"2026-01-26","type":"pipeline","source":"prnewswire.com","summary":"RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight - prnewswire.com","headline":"RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQTU1XRUJYZUpRTjhobkhIekZJdk1OeUVidDQxY1E5ZHpqdWtoWjV4bUJQbWE3ZlQ1NVlCUXlTbnJPeDVVTWRVVmx2RmozN0M4RTFvSHZxcU1LU3kyVXUzYmJ3SWxjZXlWR3c0T3YwN21QZUt6Y3FkNFJnU2pNMjBHTGhwemg0S0hzNUNkY1NjLVVfYlRaVU1melNLLW1adXFveW1SV3JuLVFKcnRQb0tua2xBWUFuLXZLNW1kXw?oc=5","date":"2025-01-09","type":"pipeline","source":"BioWorld News","summary":"Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld News","headline":"Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOWlJncjRDZVdINGZOX1pRYVdVQXVoUjhQeWlEQjNJaWh2aGludGlCUHlUcEZrOTBNVHVndE1lU2lIcVZWSk5tWU1SVFJBLXhvY1JDblI4T0lYeDFzMVhCaVZMelM2ZXlXbE02aktCdGpJUFNEelFyRDlwQ1JKT2x2TVNzWERpcXE1T1d6ZHpvVXgtczROTG91S0lOamFCSXZ2MFM0Ug?oc=5","date":"2024-08-27","type":"pipeline","source":"BioWorld News","summary":"TYK Medicines raises $74M in HKEX IPO to launch EGFR inhibitor - BioWorld News","headline":"TYK Medicines raises $74M in HKEX IPO to launch EGFR inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOMUZCVFl0WWEyODluWUdNSzI1QWptbTJVQzgyR1o0TmhVQnJrTDdhWDk5eUxXc2ltMVRncUJhMmtvci1Cdjl1ZV9SZzBVVS1oUHBlVm1GT09oMG5YZUpuSVhyM09PZmthbkFDZzN2X2ZJRDYzMEV2X3pDWndQTXlGNjkteGhBNXlIcHlIYlhmRmhNQQ?oc=5","date":"2022-11-23","type":"pipeline","source":"Yahoo Finance","summary":"Extremely Robust Brain Metastases Pipeline Featuring 45+ Companies Expected to Change the Pace of the Brain Metastases Treatment | DelveInsight - Yahoo Finance","headline":"Extremely Robust Brain Metastases Pipeline Featuring 45+ Companies Expected to Change the Pace of the Brain Metastases T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxNdk1EenJ6WDVHZHM0U3NvQVZmUV9mdFcxcU16WUpZdFdIblRqSGk5VEVkb3prVjVMVHlPX2tWemFLV1Y2ZWdBU0FyQWdMTmlrRjdvOWxQZ0lPR2ZXOGVmTDFxaW1iWVZqUTVzOUd4YTBmV2xuS1R5WFdkcEl5Y3NEQ0JxV09OQWhDM3hZU1B2MjZ5dWxJaHpneVFVY0tPRnJhU04wTUYzMkJxZFdENHN6NHJ5aE1taGU1T2VndDhSTVhWU1JKRVFqUkRtaDNBaTNKM0pSdFNVa1k3azJ6dnVSeUVxRUZKSm1zazMwVVZ1Xzg5TjQzZXE3UVVZRXZuQk9uN3M0Rnd3bkVJaXN4NGdWQmVwVQ?oc=5","date":"2022-09-09","type":"regulatory","source":"news.bms.com","summary":"U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis - news.bms.com","headline":"U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5SdFd0Zy1SWDQtOFk5UG1BN2N5VXhYT21Rb2lFUDFIUmhOX08yM19jaXc1VUs3M2ZFM1ZtOHNacTc5SUktOHB5M2xXVFU5RWVfeEt2cGN3?oc=5","date":"2021-02-15","type":"pipeline","source":"Yahoo Finance Singapore","summary":"InnoCare Pharma Limited (9969.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"InnoCare Pharma Limited (9969.HK) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}